Evaluation of waning of IgG antibody responses after rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccines: a modelling study from the PREVAC randomized trial.

• Tác giả: Marie Alexandre, Abdoul Habib Beavogui, Irina Maljkovic Berry, Natasha Dubois Cauwelaert, Seydou Doumbia, Daniela Fusco, Brian Greenwood, Mark Kieh, Jens H Kuhn, Bailah Leigh, Yves Lévy, Edouard Lhomme, Marie Poupelin, Mélanie Prague, Laura Richert, Christine Schwimmer, Samba O Sow, Rodolphe Thiébaut, Simon Valayer, Deborah Watson-Jones, Yazdan Yazdanpanah
• Ngôn ngữ: eng
• Ký hiệu phân loại: 370.157 Creativity and imagination
• Thông tin xuất bản: United States : Emerging microbes & infections , 2025
• Bộ sưu tập: NCBI
• ID: 215983

Tóm tắt

rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo are WHO-prequalified vaccination regimens against Ebola virus disease (EVD). Challenges associated with measuring long-term clinical protection warrant the evaluation of immune response kinetics after vaccination. Data from a large phase 2 randomized double-blind clinical trial (PREVAC) were used to evaluate waning of anti-Ebola virus (EBOV) glycoprotein (GP